TGEN
Tecogen Inc.
Electrical Equipment & Parts
Market Cap$120M
5Y Perf.+630.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
TGEN vs CDTX vs ACAD vs AGIO
Revenue, margins, valuation, and 5-year total return — side by side.
CDTX
Cidara Therapeutics, Inc.
Biotechnology
Market Cap$6.96B
5Y Perf.+205.1%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-54.6%
AGIO
Agios Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.64B
5Y Perf.-46.8%
TGEN vs CDTX vs ACAD vs AGIO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TGEN | CDTX | ACAD | AGIO |
|---|---|---|---|---|
| Industry | Electrical Equipment & Parts | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $120M | $6.96B | $3.86B | $1.64B |
| Revenue (TTM) | $27M | $0.00 | $1.10B | $66M |
| Net Income (TTM) | $-8M | $-185M | $376M | $-423M |
| Gross Margin | 36.3% | 100.0% | 91.5% | 82.1% |
| Operating Margin | -26.3% | -138.1% | 7.4% | -7.2% |
| Forward P/E | — | — | 50.9x | — |
| Total Debt | $3M | $4M | $52M | $62M |
| Cash & Equiv. | $12M | $190M | $178M | $89M |
TGEN vs CDTX vs ACAD vs AGIO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TGEN
CDTX
ACAD
AGIO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Tecogen Inc. (TGEN) | 100 | 730.3 | +630.3% |
| Cidara Therapeutics… (CDTX) | 100 | 305.1 | +205.1% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 45.4 | -54.6% |
| Agios Pharmaceutica… (AGIO) | 100 | 53.2 | -46.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TGEN vs CDTX vs ACAD vs AGIO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CDTX and ACAD are tied at the top with 2 categories each — the right choice depends on your priorities. ACADIA Pharmaceuticals Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. AGIO also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
TGEN
Tecogen Inc.
The Long-Run Compounder
TGEN is the clearest fit if your priority is long-term compounding.
- -3.2% 10Y total return vs CDTX's -16.0%
Best for: long-term compounding
CDTX
Cidara Therapeutics, Inc.
The Income Pick
CDTX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.87
- Lower volatility, beta 0.87, Low D/E 2.2%, current ratio 4.25x
- Beta 0.87, current ratio 4.25x
- Beta 0.87 vs TGEN's 3.43, lower leverage
Best for: income & stability and sleep-well-at-night
ACAD
ACADIA Pharmaceuticals Inc.
The Quality Compounder
ACAD is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 34.3% margin vs CDTX's -133.2%
- 26.2% ROA vs CDTX's -35.6%
Best for: quality and efficiency
AGIO
Agios Pharmaceuticals, Inc.
The Growth Play
AGIO is the clearest fit if your priority is growth exposure.
- Rev growth 48.0%, EPS growth -161.2%, 3Y rev CAGR 56.0%
- 48.0% revenue growth vs CDTX's -94.5%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs CDTX's -94.5% |
| Quality / Margins | ACAD | 34.3% margin vs CDTX's -133.2% |
| Stability / Safety | CDTX | Beta 0.87 vs TGEN's 3.43, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | CDTX | +10.7% vs AGIO's -2.4% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs CDTX's -35.6% |
TGEN vs CDTX vs ACAD vs AGIO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2024
FY 2018
FY 2025
TGEN vs CDTX vs ACAD vs AGIO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCDTXLAGGINGAGIO
Who Leads Where
ACAD leads in 2 of 6 categories
CDTX leads 2 • TGEN leads 0 • AGIO leads 0 • 1 tied
Explore the data ↓AGIOAgios Pharmaceuticals…
0leads
TGENTecogen Inc.
0leads
ACADACADIA Pharmaceutical…
2leads
CDTXCidara Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs ACADvs TGENMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
CDTX4/6
Risk & VolatilityBeta, volatility, and downside exposure
CDTX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD and CDTX operate at a comparable scale, with $1.1B and $0 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to CDTX's -133.2%. On growth, AGIO holds the edge at +137.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TGENTecogen Inc. | CDTXCidara Therapeuti… | ACADACADIA Pharmaceut… | AGIOAgios Pharmaceuti… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $27M | $0 | $1.1B | $66M |
| EBITDAEarnings before interest/tax | -$6M | -$195M | $96M | -$470M |
| Net IncomeAfter-tax profit | -$8M | -$185M | $376M | -$423M |
| Free Cash FlowCash after capex | -$10M | -$133M | $212M | -$385M |
| Gross MarginGross profit ÷ Revenue | +36.3% | +100.0% | +91.5% | +82.1% |
| Operating MarginEBIT ÷ Revenue | -26.3% | -138.1% | +7.4% | -7.2% |
| Net MarginNet income ÷ Revenue | -30.5% | -133.2% | +34.3% | -6.4% |
| FCF MarginFCF ÷ Revenue | -38.1% | -138.6% | +19.4% | -5.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -12.5% | — | +9.7% | +137.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -173.1% | -30.3% | -81.8% | -9.0% |
ACAD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — TGEN and ACAD and AGIO each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | TGENTecogen Inc. | CDTXCidara Therapeuti… | ACADACADIA Pharmaceut… | AGIOAgios Pharmaceuti… |
|---|---|---|---|---|
| Market CapShares × price | $120M | $7.0B | $3.9B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $111M | $6.8B | $3.7B | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -16.07x | -8.28x | 9.85x | -3.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 50.91x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 26.91x | — |
| Price / SalesMarket cap ÷ Revenue | 4.44x | 5460.07x | 3.61x | 30.30x |
| Price / BookPrice ÷ Book value/share | 6.11x | 8.61x | 3.15x | 1.34x |
| Price / FCFMarket cap ÷ FCF | — | — | 36.74x | — |
Evenly matched — TGEN and ACAD and AGIO each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-51 for TGEN. CDTX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to TGEN's 0.13x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs AGIO's 2/9, reflecting solid financial health.
| Metric | TGENTecogen Inc. | CDTXCidara Therapeuti… | ACADACADIA Pharmaceut… | AGIOAgios Pharmaceuti… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -50.6% | -43.7% | +35.6% | -34.1% |
| ROA (TTM)Return on assets | -24.2% | -35.6% | +26.2% | -31.7% |
| ROICReturn on invested capital | -52.7% | — | +10.0% | -26.3% |
| ROCEReturn on capital employed | -34.0% | -2.1% | +10.1% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 | 6 | 2 |
| Debt / EquityFinancial leverage | 0.13x | 0.02x | 0.04x | 0.05x |
| Net DebtTotal debt minus cash | -$10M | -$186M | -$126M | -$27M |
| Cash & Equiv.Liquid assets | $12M | $190M | $178M | $89M |
| Total DebtShort + long-term debt | $3M | $4M | $52M | $62M |
| Interest CoverageEBIT ÷ Interest expense | -46.61x | — | — | — |
ACAD leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
CDTX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CDTX five years ago would be worth $55,070 today (with dividends reinvested), compared to $4,935 for AGIO. Over the past 12 months, CDTX leads with a +1066.4% total return vs AGIO's -2.4%. The 3-year compound annual growth rate (CAGR) favors CDTX at 118.6% vs ACAD's 1.5% — a key indicator of consistent wealth creation.
| Metric | TGENTecogen Inc. | CDTXCidara Therapeuti… | ACADACADIA Pharmaceut… | AGIOAgios Pharmaceuti… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.7% | +0.2% | -13.7% | +1.3% |
| 1-Year ReturnPast 12 months | +49.2% | +1066.4% | +52.4% | -2.4% |
| 3-Year ReturnCumulative with dividends | +460.5% | +944.2% | +4.7% | +8.3% |
| 5-Year ReturnCumulative with dividends | +180.2% | +450.7% | +7.1% | -50.7% |
| 10-Year ReturnCumulative with dividends | -3.2% | -16.0% | -22.9% | -42.2% |
| CAGR (3Y)Annualised 3-year return | +77.6% | +118.6% | +1.5% | +2.7% |
CDTX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
CDTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CDTX is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than TGEN's 3.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDTX currently trades 100.0% from its 52-week high vs TGEN's 39.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TGENTecogen Inc. | CDTXCidara Therapeuti… | ACADACADIA Pharmaceut… | AGIOAgios Pharmaceuti… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.43x | 0.87x | 1.26x | 1.12x |
| 52-Week HighHighest price in past year | $12.07 | $221.42 | $27.81 | $46.00 |
| 52-Week LowLowest price in past year | $1.94 | $18.51 | $14.45 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +39.9% | +100.0% | +81.1% | +59.8% |
| RSI (14)Momentum oscillator 0–100 | 71.9 | 84.8 | 44.2 | 41.9 |
| Avg Volume (50D)Average daily shares traded | 486K | 0 | 1.8M | 1.0M |
CDTX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: TGEN as "Buy", CDTX as "Buy", ACAD as "Buy", AGIO as "Buy". Consensus price targets imply 211.2% upside for TGEN (target: $15) vs 0.1% for CDTX (target: $222).
| Metric | TGENTecogen Inc. | CDTXCidara Therapeuti… | ACADACADIA Pharmaceut… | AGIOAgios Pharmaceuti… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $15.00 | $221.50 | $34.78 | $37.75 |
| # AnalystsCovering analysts | 4 | 11 | 37 | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CDTX leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallCidara Therapeutics, Inc. (CDTX)Leads 2 of 6 categories
Loading custom metrics...
TGEN vs CDTX vs ACAD vs AGIO: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is TGEN or CDTX or ACAD or AGIO a better buy right now?
For growth investors, Agios Pharmaceuticals, Inc.
(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Tecogen Inc. (TGEN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TGEN or CDTX or ACAD or AGIO?
Over the past 5 years, Cidara Therapeutics, Inc.
(CDTX) delivered a total return of +450. 7%, compared to -50. 7% for Agios Pharmaceuticals, Inc. (AGIO). Over 10 years, the gap is even starker: TGEN returned -3. 2% versus AGIO's -42. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TGEN or CDTX or ACAD or AGIO?
By beta (market sensitivity over 5 years), Cidara Therapeutics, Inc.
(CDTX) is the lower-risk stock at 0. 87β versus Tecogen Inc. 's 3. 43β — meaning TGEN is approximately 296% more volatile than CDTX relative to the S&P 500. On balance sheet safety, Cidara Therapeutics, Inc. (CDTX) carries a lower debt/equity ratio of 2% versus 13% for Tecogen Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TGEN or CDTX or ACAD or AGIO?
By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.
(AGIO) is pulling ahead at 48. 0% versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -409. 5% for Cidara Therapeutics, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TGEN or CDTX or ACAD or AGIO?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -133. 2% for Cidara Therapeutics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -138. 1% for CDTX. At the gross margin level — before operating expenses — CDTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is TGEN or CDTX or ACAD or AGIO more undervalued right now?
Analyst consensus price targets imply the most upside for TGEN: 211.
2% to $15. 00.
07Which pays a better dividend — TGEN or CDTX or ACAD or AGIO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is TGEN or CDTX or ACAD or AGIO better for a retirement portfolio?
For long-horizon retirement investors, Cidara Therapeutics, Inc.
(CDTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Tecogen Inc. (TGEN) carries a higher beta of 3. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDTX: -16. 0%, TGEN: -3. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between TGEN and CDTX and ACAD and AGIO?
These companies operate in different sectors (TGEN (Industrials) and CDTX (Healthcare) and ACAD (Healthcare) and AGIO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: TGEN is a small-cap high-growth stock; CDTX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; AGIO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(TGEN: -12.5% · CDTX: -94.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.